Results of Operations and Financial Condition. On August 5, 2026, Adicet Bio, Inc. announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or…

Results of Operations and Financial Condition. On May 13, 2026, Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or o…

Unregistered Sales of Equity Securities. On April 27, 2026, Adicet Bio, Inc. (the Company) entered into an exchange agreement with RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P. (together, RA Capital) pursuant to which RA Capital exchanged 250,000 shares of the Company’s common stock, par value $0.0001 per share (Common Stock) for a pre-funded warrant (the Pre-Funded Warrant) to acquire 250,000 shares of Common Stock. The Pre-Funded Warrant has an exercise price of $0.0001 p…

Results of Operations and Financial Condition. On March 12, 2026, Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…

Other Events. On December 26, 2025, the Company issued a press release announcing the Reverse Stock Split and other related information. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. Cautionary Note Regarding Forward Looking Statements The disclosure in this Current Report on Form 8-K contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and ope…

Results of Operations and Financial Condition. On November 5, 2025, Adicet Bio, Inc. announced its financial results for the quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Entry into a Material Definitive Agreement. On October 7, 2025, Adicet Bio, Inc. (the Company) entered into an Underwriting Agreement (the Underwriting Agreement) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto (the Underwriters), related to an underwritten registered direct offering (the Offering) of 70,001,000 shares (the Shares) of common stock of the Company, par value $0.0001 per share (the Common Stock), and,…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported on April 7, 2025, Adicet Bio, Inc. (the Company or Adicet) received a notification letter (the Bid Price Letter) from The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.0001 per share (the Common Stock), has been below the minimum $1.00 per share re…

Other Events. On October 7, 2025, the Company announced preliminary data from its ADI-001 Phase 1 study in patients with LN and SLE. The preliminary data, as well as additional corporate updates, are summarized below. ADI-001 Phase 1 Study Preliminary Data Data highlights as of the August 31, 2025 cut-off date were as follows: • Seven patients (five LN and two SLE) were evaluated with follow-up ranging from two to nine months. • 100% of patients in the LN cohort achieved renal response, inclu…

Results of Operations and Financial Condition. On August 7, 2025, Adicet Bio, Inc. announced its financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or…

Costs Associated with Exit or Disposal Activities. On July 22, 2025, the Board of Directors of Adicet Bio, Inc. (the Company or Adicet) approved a reduction in its workforce by approximately 30% of the Company’s current employee base in connection with its strategic pipeline prioritization, as disclosed under

Other Events. On July 23, 2025, the Company announced a strategic prioritization of the Company’s pipeline intended to optimize the development of assets with the greatest potential for clinical and commercial success. The Company will focus its resources on ADI-001, currently in Phase 1 clinical studies for autoimmune indications, and ADI-212, an optimized next-generation gene-edited and cytokine-armored clinical candidate targeting prostate specific membrane antigen (PSMA). The Company has…

Results of Operations and Financial Condition. On May 6, 2025, Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or ot…

Director — Carl L. Gordon, Ph.D.: Dr. Gordon resigned from the Board and was succeeded by Michael Grissinger.

Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard On April 7, 2025, Adicet Bio, Inc. (the “Company”) received a notice from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Market unde…

Results of Operations and Financial Condition. On March 6, 2025, Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…

Termination of a Material Definitive Agreement. On November 27, 2024, Adicet Therapeutics, Inc. (the “Subsidiary”), a Delaware corporation and wholly-owned subsidiary of Adicet Bio, Inc. (the “Guarantor”, and together with the Subsidiary, the “Company”), and Banc of California (formerly known as Pacific Western Bank) (“Banc of California”) executed a payoff letter (the “Payoff Letter”) to repay in full all outstanding indebtedness and terminate all commitments and obligations, subject to cert…

Entry into a Material Definitive Agreement. On November 8, 2024, Adicet Therapeutics, Inc. (the “Subsidiary”), a Delaware corporation and wholly-owned subsidiary of Adicet Bio, Inc. (the “Guarantor”, and together with the Subsidiary, the “Company”), and Pacific Western Bank (“PacWest”) entered into a Eighth Amendment (the “Amendment”) to that certain Loan and Security Agreement, dated April 28, 2020, by and among the Subsidiary and PacWest (the “Agreement”). Pursuant to the Agreement, PacWest…

Results of Operations and Financial Condition. On November 6, 2024, Adicet Bio, Inc. announced its financial results for the quarter ended September 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Ac…

Director — Michael Kauffman, M.D., Ph.D.: Dr. Kauffman resigned from the Board and was succeeded by Dr. Klickstein.

Results of Operations and Financial Condition. On August 13, 2024, Adicet Bio, Inc. announced its financial results for the quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or…

The filing pertains to an amended compensatory plan and does not involve a change in management or officers.

Results of Operations and Financial Condition. On May 14, 2024, Adicet Bio, Inc. announced its financial results for the quarter ended March 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or o…

Entry into a Material Definitive Agreement. On March 22, 2024, Adicet Bio, Inc. (the “Company”) entered into an Open Market Sales Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time, through an “at the market” equity offering program under which Jefferies will act as sales agent or principal. Under the Sales Agreement, the Company will set the parameters for the…

Results of Operations and Financial Condition. On March 19, 2024, Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…